This information is based on a systematic review of scientific literature, and was peer-reviewed and edited by contributors to the Natural Standard Research Collaboration (www.naturalstandard.com): Julie Conquer, PhD (RGB Consulting); Gary Ferguson, ND (Southcentral Foundation); Sayuri Fujita, PharmD (Massachusetts College of Pharmacy); Nicole Giese, MS (Natural Standard Research Collaboration); Mary Giles, PharmD (University of Rhode Island); Richard Liebowitz, MD (Duke University); Shaina Tanguay-Colucci, BS (Natural Standard Research Collaboration); Ruslan Voloshin, PharmD (Massachusetts College of Pharmacy); Wendy Weissner, BA (Natural Standard Research Collaboration).
Bazzato G, Coli U, Landini S, et al. Myasthenia-like syndrome after D,L- but not L-carnitine. Lancet 5-30-1981;1(8231):1209.
Bazzato G, Mezzina C, Ciman M, et al. Myasthenia-like syndrome associated with carnitine in patients on long- term haemodialysis. Lancet 5-12-1979;1(8124):1041-1042.
Benvenga S, Ruggeri RM, Russo A, et al. Usefulness of L-carnitine, a naturally occurring peripheral antagonist of thyroid hormone action, in iatrogenic hyperthyroidism: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 2001;86(8):3579-3594.
Bohmer T, Bergrem H, Eiklid K. Carnitine deficiency induced during intermittent haemodialysis for renal failure. Lancet 1-21-1978;1(8056):126-128.
Casciani CU, Caruso U, Cravotto E, et al. Effect of L-carnitine on lipid pattern in haemodialysis. Lancet 12-13-1980;2(8207):1309-1310.
El Beshlawy A, Abd El Raouf, Mostafa F, et al. Diastolic dysfunction and pulmonary hypertension in sickle cell anemia: is there a role for L-carnitine treatment? Acta Haematol. 2006;115(1-2):91-96.
Ellaway C, Williams K, Leonard H, et al. Rett syndrome: randomized controlled trial of L-carnitine. J Child Neurol 1999;14(3):162-167.
Holme E, Greter J, Jacobson CE, et al. Carnitine deficiency induced by pivampicillin and pivmecillinam therapy. Lancet 8-26-1989;2(8661):469-473.
Jirillo E, Altamura M, Munno I, et al. Effects of acetyl-L-carnitine oral administration on lymphocyte antibacterial activity and TNF-alpha levels in patients with active pulmonary tuberculosis. A randomized double blind versus placebo study. Immunopharmacol.Immunotoxicol. 1991;13(1-2):135-146.
Lacour B, Di Giulio S, Chanard J, et al. Carnitine improves lipid anomalies in haemodialysis patients. Lancet 10-11-1980;2(8198):763-764.
Maebashi M, Kawamura N, Sato M, et al. Lipid-lowering effect of carnitine in patients with type-IV hyperlipoproteinaemia. Lancet 10-14-1978;2(8094):805-807.
Persico G, Amato B, Aprea G, et al. The early effects of intravenous L-propionyl carnitine on ulcerative trophic lesions of the lower limbs in arteriopathic patients: a controlled randomized study. Drugs Exp Clin Res 1995;21(5):187-198.
Sima AA, Calvani M, Mehra M, et al. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. Diabetes Care 2005;28(1):89-94.
Singh RB, Niaz MA, Agarwal P, et al. A randomised, double-blind, placebo-controlled trial of L-carnitine in suspected acute myocardial infarction. Postgrad.Med J 1996;72(843):45-50.
Thomas S, Fischer FP, Mettang T, et al. Effects of L-carnitine on leukocyte function and viability in hemodialysis patients: A double-blind randomized trial. Am J Kidney Dis 1999;34(4):678-687.